Burning Rock Biotech
58 hedge funds and large institutions have $474M invested in Burning Rock Biotech in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 5 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
53% more funds holding
Funds holding: 38 → 58 (+20)
20% more capital invested
Capital invested by funds: $396M → $474M (+$77.9M)
0.48% more ownership
Funds ownership: 1.89% → 2.37% (+0.48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$32.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.2M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$15.2M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
+$10.8M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$15.7M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$10M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$4.43M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$3.11M |
| 5 |
GAM
Greenwoods Asset Management
Grand Cayman,
Cayman Islands
|
-$2.51M |
BNR Hedge Fund Activity: Q4 2020 in Review
58 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q4 2020, worth a combined $474M — up 20% from $396M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BNR positions and 5 closed out — a net gain of 20 holders — while 18 added to existing stakes and 7 trimmed.
The largest buyer was Jennison Associates, adding an estimated $32.7M. The largest seller was OrbiMed, cutting an estimated $15.7M.
- 58 institutional investors held Burning Rock Biotech (BNR) as of Q4 2020, up from 38 in Q3 2020.
- Funds reported $474M of Burning Rock Biotech stock for Q4 2020, up 20% quarter-over-quarter.
- 25 funds opened new Burning Rock Biotech positions in Q4 2020 and 5 closed out, a net change of +20 holders.
- The largest Burning Rock Biotech buyer in Q4 2020 was Jennison Associates, an estimated $32.7M added.
- The largest Burning Rock Biotech seller in Q4 2020 was OrbiMed, an estimated $15.7M sold.
Based on aggregated 13F filings for Q4 2020.